← MDxHealth SA
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation | $3.4m | $3.3m | $1.4m | $1.7m | $2.4m | $3.1m | $4.0m | $4.2m | |
| Amortization of intangible assets | — | — | $1.6m | $3.2m | $4.5m | $4.9m | $5.2m | — | |
| Share-based compensation | $872k | $1.3m | $1.2m | $867k | $665k | $1.7m | $2.2m | $2.4m | |
| Decrease / (increase) in receivables | $12.2m | $2.9m | ($1.4m) | ($5.1m) | ($1.7m) | ($3.2m) | $2.3m | — | |
| Provision for inventory obsolescence | — | — | — | — | — | — | $683k | — | |
| Increase in inventories | $615k | ($1.1m) | $413k | ($416k) | ($452k) | ($1.1m) | ($1.9m) | — | |
| Increase in payables | ($2.5m) | $234k | $1.3m | $4.0m | $20k | $458k | $550k | — | |
| Net cash outflow from operating activities | ($22.3m) |
($20.2m)
+9.17%
|
($22.5m)
-11.38%
|
($34.1m)
-51.31%
|
($21.5m)
+36.99%
|
($18.5m)
+13.80%
|
($2.2m)
+88.19%
|
($1.0m)
+52.08%
|
|
| Purchase of property, plant and equipment | ($73k) | ($537k) | ($896k) | ($2.8m) | ($2.7m) | ($1.2m) | ($1.2m) | — | |
| Net cash outflow from investing activities | ($73k) | ($537k) | ($885k) | ($29.2m) | ($3.9m) | ($1.6m) | ($18.6m) | — | |
| Repayment of loan obligation and debt extinguishment costs | — | $0 | $0 | ($10.8m) | ($250k) | ($39.5m) | ($324k) | — | |
| Net cash inflow from financing activities | $18.0m |
$14.3m
-20.46%
|
$66.5m
+365.35%
|
$20.8m
-68.66%
|
$32.3m
+54.89%
|
$44.6m
+38.16%
|
$3.0m
-93.35%
|
— | |
| Net decrease (-) / increase (+) in cash and cash equivalents | — | ($6.5m) | $43.1m | ($42.4m) | $6.9m | $24.4m | ($17.8m) | — | |
| Cash and cash equivalents at beginning of the financial year | $26.2m | $22.1m | $16.0m | $58.5m | $15.5m | $46.8m | $29.0m | — | |
| Effect on exchange rate changes | $244k | $394k | ($520k) | ($555k) | $25k | ($14k) | $16k | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Operating loss | ($43.2m) |
($27.1m)
+37.17%
|
($26.8m)
+1.04%
|
($37.9m)
-41.20%
|
($27.3m)
+27.90%
|
($24.7m)
+9.53%
|
($14.4m)
+41.72%
|
— | |
| Operating changes in fair value of contingent liabilities | — | — | — | — | — | — | ($962k) | — | |
| Other non-cash transactions | $1k | $26k | ($325k) | ($473k) | $421k | $286k | $140k | — | |
| Cash used in operations before working capital changes | ($32.6m) | ($22.2m) | ($22.9m) | ($32.6m) | ($19.4m) | ($14.7m) | ($3.1m) | — | |
| Acquisition and generation of intangible assets | — | $0 | $0 | ($1.4m) | ($2.3m) | ($971k) | — | — | |
| Earnout payment (GPS acquisition) | — | — | — | — | — | ($555k) | ($8.3m) | — | |
| Cash from acquisition of Exosome Diagnostics | — | — | — | — | — | — | $755k | — | |
| Interest received | $0 | $0 | $11k | $125k | $1.1m | $1.1m | $1.5m | $1.2m | |
| Proceeds from issuance of shares, net of transaction costs | $9.6m | $13.9m | $68.6m | $0 | $39.6m | $40.7m | — | — | |
| Proceeds from loan obligation | — | $2.3m | $0 | $34.3m | — | $53.0m | $24.2m | — | |
| Amendment fee related to OrbiMed / GPS agreement | — | — | — | — | ($250k) | ($550k) | — | — | |
| Payment of lease liability | ($815k) | ($831k) | ($1.1m) | ($1.4m) | ($1.6m) | ($1.9m) | ($2.3m) | — | |
| Payment of interest | ($324k) | ($1.1m) | ($1.0m) | ($1.4m) | ($3.6m) | ($6.7m) | ($9.7m) | — | |
| Other financial expenses | — | — | — | — | ($190k) | ($477k) | ($596k) | — |